Vanda Schizophrenia Drug Patentable, Fed. Circ. Says
Law360 (April 13, 2018, 11:17 PM EDT) -- The Federal Circuit on Friday upheld a patent covering Vanda Pharmaceuticals Inc.’s schizophrenia drug Fanapt, finding it met the U.S. Supreme Court’s Mayo standard by outlining a specific method of using...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
